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Background:  We  have developed  a  new oral  vaccine  against  enterotoxigenic  Escherichia  coli  (ETEC),  which
is the most  common  cause  of  bacterial  diarrhea  in  children  in  developing  countries  and  in  travelers.
Methods:  The  vaccine  was  tested  for safety  and  immunogenicity  alone  and  together  with  double-mutant
heat-labile  toxin  (dmLT)  adjuvant  in a  double-blind,  placebo-controlled  Phase  I study  in  129  Swedish
adults.  The  vaccine  consists  of  four  inactivated  recombinant  E.  coli strains  overexpressing  the  major  ETEC
colonization  factors  (CFs)  CFA/I,  CS3,  CS5,  and  CS6  mixed  with  an  LT  B-subunit  related toxoid,  LCTBA.  Vol-
unteers  received  two  oral  doses  of  vaccine  alone,  vaccine  plus  10 g or 25  g dmLT  or placebo.  Secretory
IgA  antibody  responses  in  fecal  samples  and  IgA  responses  in  secretions  from  circulating  intestine-derived
antibody  secreting  cells were  assessed  as  primary  measures  of vaccine  immunogenicity.
Results:  The  vaccine  was  safe  and  well  tolerated;  adverse  events  were  few  and  generally  mild  with  no
signiﬁcant  differences  between  subjects  receiving  placebo  or vaccine  with  or without  adjuvant.  As many
as 74%  of  subjects  receiving  vaccine  alone  and  83%  receiving  vaccine  plus 10 g dmLT  showed  signiﬁcant
mucosal  IgA  responses  to  all ﬁve  primary  vaccine  antigens  and  about  90%  of  all  vaccinees  responded  to
at least  four  of  the antigens.  Subjects  receiving  vaccine  plus  10  g  dmLT  responded  with  signiﬁcantly
increased  intestine-derived  anti-CS6  responses  compared  to subjects  receiving  vaccine  alone.
Conclusions:  The  vaccine  was  safe  and  broadly  immunogenic.  dmLT  further  enhanced  mucosal  immune
responses  to CF  antigens  present  in low  amounts  in the  vaccine.  Based  on  these  encouraging  results,
the  vaccine  will  be  tested  for safety  and immunogenicity  in  different  age  groups  including  infants  in
Bangladesh  and for protective  
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. Introduction
Although enterotoxigenic Escherichia coli (ETEC) is the most
requent bacterial cause of diarrhea in children in developing
ountries and the major cause of travelers’ diarrhea, no vaccine is
et available against ETEC disease [1–3]. ETEC disease occurs after
ngestion of ETEC leading to bacterial colonization of the intestinal
ucosa by means of surface-expressed colonization factors (CFs)
n the bacteria and production of a heat-labile toxin (LT) and/or a
eat-stable toxin (ST) that induce watery diarrhea [3,4]. Immune
rotection is mediated by anti-CF and/or anti-LT antibodies pro-
uced locally in the intestine [2,5].
We have previously developed an oral vaccine consisting of
nactivated ETEC bacteria expressing prevalent CFs and recombi-
antly produced cholera toxin binding subunit (CTB) [5,6]. This
accine was shown to be safe and immunogenic in children and
dults in endemic areas and conferred protection against moder-
te/severe diarrhea in adult travelers [5,7]. However, the protective
fﬁcacy in developing-country children was not signiﬁcant and a
ull dose of vaccine, but not a quarter dose, induced vomiting in
hildren 6–17 months old [2,8]. Therefore, we have now developed
 modiﬁed second-generation oral ETEC vaccine with the aim to
mprove its immunogenicity without increasing the dosage and to
e able to give a reduced dose to infants [5,9]. Our approach has
een to construct recombinant E. coli strains expressing increased
mounts of the most prevalent CFs [10] and to include a CTB/LTB
ybrid protein (LCTBA), which induces stronger anti-LT responses
han CTB in both mice and humans [11,12]. We  have also broad-
ned the coverage of the vaccine by including a strain expressing
he prevalent colonization factor CS6 in immunogenic form [13].
his new multivalent ETEC vaccine (MEV) contains four different
nactivated E. coli strains expressing substantially higher levels of
FA/I, CS3, CS5 and CS6 than in the ﬁrst-generation vaccine, plus
CTBA [9]. In addition, we have evaluated the possibility to further
nhance the immunogenicity of the vaccine by coadministration
ith the double-mutant LT (dmLT) adjuvant [14]. Our preclinical
tudies have demonstrated that addition of dmLT to MEV  signiﬁ-
antly improved both the anti-CF and anti-LT responses following
ral immunization [9].
The primary objectives of this study were to evaluate the safety
nd mucosal immunogenicity of MEV  and to explore if the immuno-
enicity of the vaccine might be further enhanced by addition
f dmLT adjuvant. Serum anti-LT and toxin-neutralizing immune
esponses were determined as secondary and exploratory meas-
res. These aspects were addressed in a Phase I clinical trial
ncluding 129 adult Swedish volunteers given either vaccine alone
r together with two different dosages (10 g and 25 g) of dmLT;
 matched control group received buffer only.
The results show that the vaccine was safe and well tolerated,
oth when given alone and in combination with dmLT adjuvant. The
accine induced signiﬁcant mucosal and intestine-derived immune
esponses to all major vaccine antigens and dmLT further enhanced
ucosal immune responses to the CF antigens present in low
mounts in the vaccine.
. Materials and methods
For additional information, see Supplementary material.
.1. Study designThis was a four-armed, randomized, double-blind, placebo-
ontrolled, single-center Phase I trial. The study was  approved by
he Ethical Review Board in the Gothenburg Region, the Western2 (2014) 7077–7084
Institutional Review Board, USA and the Swedish Medical Product
Agency.
2.2. Randomization and masking
Healthy adult subjects, 18 to 43 years, were randomized into
one of four groups (A–D); each group was  given two oral doses two
weeks apart of one of the following treatments: (A) vaccine buffer
alone (n = 34), (B) MEV  alone (n = 35), (C) MEV  plus 10 g dmLT
(n = 30) or (D) MEV  plus 25 g dmLT (n = 30). A computer-generated
randomization list was  prepared by a statistician otherwise not
involved in the study.
2.3. Vaccine
MEV  (also called Etvax) consists of four inactivated recombinant
E. coli strains (ETEX 21–24) which overexpress CFA/I, CS3, CS5 and
CS6, respectively, mixed with LCTBA [9]. The CFA/I, CS3 and CS5
expressing strains, all based on a toxin-negative O78 ETEC strain,
were inactivated with formalin and the CS6 expressing E. coli K12
strain with phenol to retain CF expression on the bacterial sur-
face [10,13]. LCTBA is a recombinantly produced LTB/CTB hybrid
protein in which seven amino acids in CTB have been replaced
by corresponding amino acids of LTB [12]. dmLT (R192G/L211A)
is an LT-derived protein which contains two genetic substitutions
in the A subunit which eliminates the enterotoxic activity without
removing the adjuvant activity [14].
2.4. Procedures
Volunteers received two  oral doses of vaccine ± dmLT in bicar-
bonate buffer or placebo (buffer alone) two weeks apart (day 0 and
day 14 ± 2). Fecal samples were collected on days 0, 7 ± 1, 14 ± 2,
19 ± 1, 21 ± 1 and 28 ± 2, blood samples for isolation of peripheral
blood mononuclear cells (PBMCs) on days 0, 7 ± 1, 19 and 21 ± 1
and serum samples on days 0, 7 ± 1, 14 ± 2, 19 ± 1, 21 ± 1, 28 ± 2
and 40–56.
Safety was  determined by evaluation of adverse event (AE)
reports (diary cards and interviews) from day 0 until day 40–56, by
clinical chemistry and hematology tests performed at screening and
on days 7 ± 1 and 21 ± 1 and by physical examination at screening
and on day 40–56. Solicited AEs listed in the study diaries were
gastrointestinal symptoms (i.e. abdominal pain, nausea, vomiting,
diarrhea, loose stools) plus fever.
Mucosal immune responses were evaluated by measuring
intestine-derived antibody secreting cells (ASCs) and intestinal
secretory IgA (SIgA) responses in fecal extracts. Systemic immune
responses were analyzed by measuring serum antibody levels.
PBMCs were isolated and used for ASC analyses by the antibodies
in lymphocyte supernatants (ALS) and ELISPOT assays as described
[11]. ASCs were detected by the ELISPOT technique using plates
coated with in-house puriﬁed CFA/I, CS3, CS5 or GM1  ganglioside
plus LTB or CS6 (Gift from F. Cassel) [6,11]. Fecal samples were
immediately frozen at home by the subjects; fecal extracts were
subsequently prepared and stored at −70 ◦C [11]. Antibody levels
in ALS specimens, fecal extracts and sera were analyzed by ELISA
using plates coated with CFA/I, CS3, CS5, CS6, GM1  plus LTB or O78
LPS [9,11]. Fecal antibody levels were determined as the antigen-
speciﬁc SIgA titer divided by the total SIgA concentration of each
sample [15]. LT toxin neutralization titers were determined using
the Y1 adrenal cell assay [16].2.5. Endpoints and statistical analyses
Safety endpoints were deﬁned as absence of any vaccine-
related serious AEs and not signiﬁcantly higher frequencies of
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Table  1
Subject demographics (safety analysis set).
(A) Placebo (n = 34) (B) Vaccine (n = 35) (C) Vaccine + 10 g dmLT (n = 30) (D) Vaccine +25 g dmLT (n = 30) Totala (n = 129)
Age (years)
Mean (SD) 24.5 (4.3) 26.1 (4.7) 25.8 (5.0) 24.5 (3.1) 25.2 (4.4)
Range  19–40 20–39 20–43 18–30 18–43
Gender (no and freq. of subjects)
Female 15 (44%) 19 (54%) 17 (57%) 8 (27%) 59 (46%)
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a 98% of the subjects were white Caucasians.
accine-related severe AEs in each of the vaccine groups than in the
lacebo group. Primary immunogenicity endpoints were deﬁned
s induction of immune responses in any of the vaccine groups in
ither of the primary assays proposed (fecal SIgA or ALS IgA) to at
east four of the ﬁve primary vaccine components (CFA/I, CS3, CS5,
S6 and LTB).
The magnitudes of immune responses (fold rises) were cal-
ulated as the post-immunization divided by pre-immunization
ntibody levels. Statistical differences were evaluated using t-
est (magnitudes, ELISA results), Mann–Whitney test (magnitudes,
oxin neutralization results) and Fisher’s exact test (frequen-
ies) with Holm’s correction for multiple testing [17]. Differences
etween vaccine groups and the placebo group were evaluated
sing one-tailed statistical tests; all other statistical tests were two-
ailed. P-values <0.05 were considered signiﬁcant.
. Results
.1. Study subjects
Of 161 subjects screened, 129 were enrolled with 30–35 sub-
ects in each of the four study groups (Table 1 and Supplementary
aterial; Fig. 1). The age and gender distributions were comparable
n Groups A, B and C, but more males were randomized to Group D
Table 1)..2. Safety
Overall, MEV  administered alone and in combination with dmLT
as safe and well tolerated. No serious AEs were reported and
ig. 1. Magnitudes of IgA responses against the ﬁve primary vaccine antigens (LTB, CFA
accine (MEV) alone, (C) vaccine plus 10 g dmLT and (D) vaccine plus 25 g dmLT. Max
oses  of vaccine are indicated. *** P < 0.001 and ** P < 0.01 for comparisons of vaccine group
roup  C with group B. ## P < 0.01 for comparison of Group D with Group C.22 (73%) 70 (54%)
the recorded AEs were mainly mild and not signiﬁcantly differ-
ent among any of the vaccine groups (B, C, D) and the placebo
group (A). The addition of dmLT did not alter the safety proﬁle.
Altogether 89 solicited symptoms, deemed to be possibly or proba-
bly related to treatment, were recorded (Table 2); these AEs did not
differ in either frequency or intensity between the different study
groups. No signiﬁcant changes of other clinical parameters, includ-
ing serum chemistry and hematology, were observed in any of the
volunteers.
3.3. Immunogenicity
3.3.1. Intestine-derived blood ASC responses
ASC responses against the primary vaccine antigens were stud-
ied by counting IgA ASCs by the ELISPOT method as well as by
measuring antibody levels in lymphocyte secretions by the ALS
method in the initial 43 randomized subjects. Since the frequen-
cies of responses against all antigens were comparable using the
two methods (data not shown), the ALS method was used in all
subsequent study subjects as the sole measure of ASC responses.
The majority of the subjects in each of the vaccine groups (B, C,
D) responded with increased IgA antibody levels to all ﬁve primary
antigens in ALS specimens (Fig. 1 and Table 3); in contrast, only a
few responders were recorded in the placebo group (A). Both the
magnitudes of responses and frequencies of responders were sig-
niﬁcantly higher in all the vaccine groups than in the placebo group.
Responses to all antigens peaked 5 days after the second dose in
a majority of the vaccinees. Highest and most frequent responses
were observed against LTB and CS3 in all vaccine groups. Evalua-
tion of the effect of the dmLT adjuvant revealed signiﬁcantly higher
/I, CS3, CS5 and CS6) in ALS specimens from volunteers receiving (A) placebo, (B)
imum fold rises (geometric mean (GM) + SEM) in antibody levels after one or two
s (B, C and D, respectively) with the placebo group (A). # P < 0.05 for comparison of
7080 A. Lundgren et al. / Vaccine 32 (2014) 7077–7084
Table  2
Numbers of solicited AEs with possible or probable relationshipa with treatment (safety analysis set).
(A) Placebo (B) Vaccine (C) Vaccine + 10 g dmLT (D) Vaccine + 25 g dmLT
Dose 1
(n = 34)
Dose 2
(n = 34)
Dose 1
(n = 35)
Dose 2
(n = 34)
Dose 1
(n = 30)
Dose 2
(n = 30)
Dose 1
(n = 30)
Dose 2
(n = 28)
Nausea 3b (9%)c 6 [1]d (18%) 6 (17%) 5 [2] (15%) 6 [1] (20%) 7 [4] (23%) 2 [1] (7%) 2 [1] (7%)
Vomiting 0 0 0 0 0 2 (7%) 0 1 (4%)
Diarrheae 1 (3%) 0 0 0 1 (3%) 1 (3%) 0 0
Loose  stools 2 (6%) 1 (3%) 3 (9%) 1 (3%) 2 (7%) 4 (13%) 5 (17%) 3 (11%)
Stomach ache 5 [1] (15%) 3 [1] (9%) 2 (6%) 4 (12%) 1 (3%) 1 [1] (3%) 7 (23%) 1 (4%)
Feverf 0 0 0 0 1 (3%) 0 0 0
Total  11 [1] 10 [2] 11 10 [2] 11 [1] 15 [5] 14 [1] 7 [1]
P > 0.05 for all comparisons of vaccine groups (B, C and D) with the placebo group (A) and comparisons between the vaccine groups.
a Study physicians judged the relation to immunization (unlikely, possible, probably, or unclassiﬁable) based on experiences from previous ETEC vaccine studies, including
a  temporal relationship with vaccination, i.e. within 72 h [7].
b Numbers of AEs of any intensity; mild, i.e. no interference with normal activity, or moderate, i.e. partial interference. No severe AEs, i.e. preventing normal activity, which
were  deemed possibly/probably related to vaccination, were recorded.
c Frequencies of AEs of any intensity.
d Numbers of AEs of moderate intensity are indicated in square brackets.
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Pe Diarrhea was deﬁned as three or more loose stools within 24 h; the reported ca
f Fever was deﬁned as >37.7 ◦C orally or 38.0 ◦C rectally.
2.3-fold, P = 0.04) magnitudes of ALS responses to CS6 in the group
eceiving vaccine plus 10 g dmLT (C) than in the group receiving
accine alone (B) (Fig. 1). Magnitudes and frequencies of responses
o LTB, CFA/I and CS5 also tended to be higher in Group C than in
roup B.
.3.2. Fecal antibody responses
A majority of volunteers in each of the vaccine groups (B, C, D)
esponded with increased speciﬁc SIgA/total SIgA to all the primary
ntigens in fecal specimens (Fig. 2 and Table 3). Both the magni-
udes and frequencies of responders were signiﬁcantly higher in
ll of the vaccine groups than in the placebo group. Comparable
requencies of responders were observed after the ﬁrst and sec-
nd dose. No signiﬁcant differences in frequencies or magnitudes
f responses were recorded between the different vaccine groups..3.3. Combined intestine-derived ASC and fecal antibody
esponses
Analysis of any mucosal immune response, i.e. fecal SIgA and/or
LS IgA responses against the primary antigens, showed that a high
ig. 2. Magnitudes of IgA responses (speciﬁc SIgA/total SIgA) against the ﬁve primary vac
lone,  (C) vaccine plus 10 g dmLT and (D) vaccine plus 25 g dmLT. Maximum fold rise
 < 0.001 and ** P < 0.01 for comparisons of vaccine groups (B, C and D, respectively) with  diarrhea were all mild, consisting of 3–4 loose stools within 24 h.
proportion (74–83%) of the vaccinees responded to all the 5 pri-
mary antigens, with the highest frequency in Group C, and 85–91%
responded to ≥4 of the antigens (Table 4).
3.3.4. Serum antibody responses
The magnitudes and frequencies of serum IgA and IgG antibody
responses against LTB were high in all vaccine groups (Fig. 3). The
responses were higher after the second dose, peaking on day 21
(IgA) or day 21–28 (IgG) in most subjects. The frequencies and mag-
nitudes of IgA and IgG responses in Group C were slightly higher
than in Group B and signiﬁcantly higher than in Group D. The LT
neutralizing responses closely resembled the titer increases deter-
mined by ELISA (Fig. 3). Anti-LT serum antibody responses were also
compared with those induced in recent trial of a ﬁrst-generation
ETEC vaccine containing CTB (for results of this comparison, see
Supplementary material) [11]. The frequencies of IgA responses
against the different CFs in serum were low (3–19%) and no signif-
icant differences between the different vaccine groups were seen
(data not shown).
cine antigens in fecal specimens from volunteers receiving (A) placebo, (B) vaccine
s (GM + SEM) in antibody levels after one or two doses of vaccine are indicated. ***
the placebo group (A).
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Table  3
Frequencies of IgA respondersa against the different primary vaccine antigens in ALS and fecal specimens (per protocol analysis sets).
(A) Placebo (B) Vaccine (C) Vaccine + 10 g dmLT (D) Vaccine + 25 g dmLT
ALS
LTB 1/29 (3%, 0.1–18)b 26/29 (90%, 73–98) 28/29 (97%, 82–99) 22/26 (85%, 65–96)
CFA/I 1/24 (4%, 0.1–21) 15/27 (56%, 35–75) 20/28 (71%, 51–87) 17/24 (71%, 49–87)
CS3  2/24 (8%, 1–27) 24/27 (89%, 71–98) 23/28 (82%, 63–94) 21/24 (88%, 68–97)
CS5  1/24 (4%, 0.1–21) 15/27 (56%, 35–75) 19/28 (68%, 48–84) 14/24 (58%, 37–78)
CS6  3/24 (13%, 3–32) 15/27 (56%, 35–75) 20/28 (71%, 51–87) 15/24 (63%, 41–81)
Feces
LTB  2/28 (7%, 0.9–24) 21/29 (72%, 53–87) 21/25 (84%, 64–95) 16/24 (67%, 45–84)
CFA/I 0/26 (0%, 0–13) 20/30 (67%, 47–83) 14/24 (58%, 37–78) 12/24 (50%, 29–71)
CS3  2/26 (8%, 1–25) 21/30 (70%, 51–85) 12/24c (50%, 29–71) 14/24 (58%, 37–78)
CS5  1/26 (4%, 0.1–20) 21/30 (70%, 51–85) 14/24 (58%, 37–78) 13/24 (54%, 33–74)
CS6  0/26 (0%, 0–13) 18/30 (60%, 41–77) 13/24 (54%, 33–74) 16/24 (67%, 45–84)
P < 0.001 for comparisons of all vaccine groups (B, C and D, respectively) with the placebo group (A) for all primary antigens in both ALS and fecal analyses.
a Cumulative response rates after one or two immunizations. Fold rises ≥2 were considered as responses in both ALS and fecal assays [6,11].
b Percentage of responders, 95% CI.
c If only subjects with a day 0 specimen were included in the analysis, 10/16 subjects (63%) responded to CS3 in fecal specimens. For all other antigens and groups,
comparable frequencies were recorded if all subjects or only subjects with a day 0 specimen were included.
Table 4
Frequencies of IgA responders against different numbers of primary vaccine antigens in ALS and/or fecal specimens.
Frequency of subjectsa
responding to
(A) Placebo (n = 20)
(%)
(B) Vaccine (n = 23)
(%)
(C) Vaccine + 10 g
dmLT (n = 23) (%)
(D) Vaccine + 25 g
dmLT (n = 20) (%)
5 antigensb 0 74 83 75
4  antigens 0 17 4 10
3  antigens 5 0 4 0
2  antigens 10 4 4 10
1  antigen 5 0 4 0
0  antigen 80 4 0 5
3
O
p
F
i
d
T
ra Only subjects from whom both fecal and ALS specimens were available.
b LTB, CFA/I, CS3, CS5, CS6.
.3.5. Immune responses against O78 LPS
High rates of mucosal and serum antibody responses against
78 LPS were recorded in all vaccine groups. ALS responses were
articularly frequent, with 96–100% of the vaccinated subjects
ig. 3. Magnitudes of responses and frequencies of ELISA IgA and IgG responders again
n  serum from volunteers receiving (A) placebo, (B) vaccine alone, (C) vaccine plus 10 
oses  of vaccine are indicated (GM + SEM). IgA and IgG serum antibody responses were d
oxin  neutralization responses were deﬁned as fourfold increases in post- compared to p
espectively) with the placebo group (A). # P < 0.05 and ## P < 0.01 for comparison of Grouresponding (Table 5). Responses in Group D tended to be lower
and less frequent than in Groups B or C. The antibody responses to
O78 LPS were comparable after the ﬁrst and the second dose in all
sample types.
st LTB and of LT neutralizing antibodies, determined by the Y1 adrenal cell assay,
g dmLT and (D) vaccine plus 25 g dmLT. Maximum fold rises after one or two
eﬁned as twofold increases in post- compared to pre-vaccination samples [6,11].
re-vaccination samples. *** P < 0.001, for comparisons of vaccine groups (B, C and D,
p D with Group C.
7082 A. Lundgren et al. / Vaccine 32 (2014) 7077–7084
Table  5
Frequencies of IgA responders and magnitudes of responses against O78 LPS in ALS, fecal and serum specimens (per protocol analysis sets).
(A) Placebo (B) Vaccine (C) Vaccine + 10 g dmLT (D) Vaccine + 25 g dmLT
Resp. freq.a Magn.b Resp. freq. Magn. Resp. freq. Magn. Resp. freq. Magn.
ALS 0/28 (0%, 0–0.1)c 1 (1–1) 29/29 (100%, 88–100) 44 (28–71) 28/28 (100%, 88–100) 55 (35–87) 24/25 (96%, 80–100) 34 (20–59)
Feces  4/26 (15%, 4–35) 1 (1–2) 21/30 (70%, 51–85) 4 (2–5) 17/24 (71%, 49–87) 3 (2–6) 13/24 (54%, 33–74) 2d (1–4)
Serum  2/33 (6%, 0.7–20) 1 (1–1) 26/34 (76%, 59–89) 4 (3–5) 23/30 (77%, 58–90) 5 (3–7) 20/26 (77%, 56–91) 3 (2–4)
P < 0.001 for comparisons of vaccine groups (B, C and D, respectively) with the placebo group (A) for both frequencies and magnitudes in all assays, with one exception, as
indicated.
a Cumulative response rates after one or two immunizations. Fold rises ≥2 were considered as responses in all assays [6,11].
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c Percentage of responders, 95% CI.
d P < 0.01.
. Discussion
The MEV  (Etvax vaccine) was found to be safe and well tolerated.
nly mild, and in a few instances moderate, AEs were recorded
nd neither the frequency nor intensity of AEs differed among sub-
ects immunized with MEV  or placebo. These results are consistent
ith data from several studies of the ﬁrst generation ETEC vac-
ine as well as a prototype second generation ETEC vaccine, which
ere found to be safe and well tolerated in adults [6,7,11]. The
EV  was also well tolerated when administered together with
mLT adjuvant, with no differences in frequency or intensity of AEs
bserved between subjects receiving MEV  plus either dose of dmLT
r MEV  alone. These results support that the dmLT protein is more
ttenuated compared to single-mutant LT (mLT; LT(R192G)), an LT-
erived adjuvant containing only one of the two mutations present
n dmLT [18]. Thus, previous studies have shown that combinations
f mLT, at comparable doses as used of dmLT in this study, and
ral whole cell Helicobacter and Campylobacter vaccines, induced
nacceptable gastrointestinal reactions ([19] and Bourgeois et al.,
npublished data). The safety and tolerability of the MEV-dmLT
ombinations demonstrated in this trial support the rationale of
urther testing of such combinations in children and infants.
Evaluation of intestine-derived immune responses by the ALS
ethod revealed strong responses against LTB in about 90% of the
accinated subjects; these responses were about twofold higher in
ubjects given vaccine plus 10 g of dmLT than vaccine alone. The
accine also induced highly signiﬁcant ALS responses against all of
he CFs in 60–90% of the vaccinees as well as signiﬁcant fecal SIgA
esponses to all ﬁve primary antigens in 60–80% of the immunized
olunteers. These results conﬁrm the encouraging results obtained
hen testing a prototype vaccine consisting of a CFA/I overexpress-
ng strain and LCTBA in a previous Phase I trial [11] and support
hat the new vaccine, even in the absence of adjuvant, is highly
mmunogenic. The magnitudes of ALS responses against CS6, which
s the CF antigen present in the lowest amount in MEV, were further
ncreased in subjects receiving vaccine plus 10 g of dmLT com-
ared to those receiving vaccine alone. There was also a trend for
igher ALS responses against CFA/I and CS5 in subjects receiving
accine plus 10 g of dmLT, whereas ALS responses against CS3,
hich is present in considerably higher amounts in MEV  than the
ther CFs, were not enhanced by addition of adjuvant. These results
re consistent with the dose-sparing effect of dmLT shown in mice
mmunized with decreasing doses of vaccine [9]. Thus, it is pos-
ible that the administration of a high dose of LCTBA and highly
mmunogenic CF-expressing bacteria may  have masked some of
he potential adjuvant activity of dmLT in this study.
Interestingly, when combining immune responses assessed by
ither or both of the two mucosal immunogenicity assays, about
0% of the subjects receiving vaccine alone or together with dmLT
ad responded to all ﬁve primary antigens and about 90% to at
east four of the antigens. Thus, the primary hypothesis of the
tudy, i.e., that at least 50% of the subjects in any of the vaccinegroups should mount a mucosal immune response to at least four
of the ﬁve primary vaccine antigens, was  strongly supported and
the results clearly exceeded the expectations. The comparatively
high and frequent mucosal immune responses recorded against
CS6 are particularly important since the ﬁrst-generation formalin-
inactivated ETEC vaccine did not induce any immune responses to
this prevalent CF in humans [5]. Hence, our approach to use CS6
expressing bacteria inactivated with phenol, which preserves CS6
immunogenicity [13], rather than formalin has been successful.
Increased preimmunization antibody levels, i.e. titers above
background levels, were detected in some of the subjects, particu-
larly against the CS3 antigen (data not shown), suggesting previous
exposure to ETEC or other microorganisms expressing immunolog-
ically related proteins. Previous exposure to such antigens, as well
as different host genetic factors, may  partially explain the varia-
tion in magnitude and breadth of immune responses observed in
different vaccinees. Thus, it was recently shown that ETEC infec-
tion may  induce memory B cells to ETEC CFs and LT that may
mediate an anamnestic response to reexposure to ETEC [20] and
probably also to corresponding antigens in MEV. Furthermore, we
have previously shown that individuals with certain blood groups
are more susceptible to infection with ETEC expressing certain CFs,
and then most likely respond more strongly to corresponding vac-
cine antigens [21]. The inﬂuence of immunological memory and
host genetics on immune responses to MEV  will be addressed in
follow-up studies.
Our ﬁnding of a positive effect of the lower dose of dmLT adju-
vant on immune responses to antigens expressed in lower amounts
supports the rationale to evaluate this adjuvant further. Of particu-
lar interest would be to assess the adjuvant effect in malnourished
children in developing countries who are known to respond less
well to oral vaccines [22]. Furthermore, previous studies with the
ﬁrst-generation ETEC vaccine have suggested that lower doses of
vaccine might be needed to improve tolerability in younger age
groups [8].
The observed lack of an effect of the higher dose of dmLT on the
anti-LTB and anti-CF responses indicates the need to determine
the optimal dosage of dmLT when given together with different
vaccines in future clinical trials. The reason for the lack of an
immune-enhancing effect of the higher dose of dmLT in this study
is unclear. However, a related phenomenon was  observed when a
single, oral dose of dmLT was given to human volunteers where
100 g was  found to be less immunogenic than 50 g doses [23].
Since studies to date have only investigated the inﬂuence of dmLT
on immune responses shortly after immunization, it will also be
important to evaluate the effect of different dosages of dmLT on
long-term immunity, including immunological memory and pro-
tection against infection in future studies. The excellent safety of
the vaccine-adjuvant combinations demonstrated in this trial will
facilitate follow-on studies to optimize dmLT-vaccine formulations.
MEV  also induced systemic IgA and IgG responses to LTB
in serum in almost all vaccinated volunteers, with the highest
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esponse rate (97%) in the group receiving vaccine plus 10 g dmLT.
ndeed, the combination of MEV  with 10 g dmLT gave rise to com-
arable anti-LTB responses, both in IgA and IgG, as induced by a
ourfold higher dose of LCTBA in a previous study [11]. Interest-
ngly, the anti-LTB responses determined by ELISA were closely
irrored by increases in LT neutralizing titers, supporting that anti-
TB responses reﬂect functional LT immunity. dmLT may  also be
apable of enhancing systemic anti-toxin immune responses, as
uggested by the ﬁnding (see Supplementary material) that MEV
lus 10 g dmLT induced signiﬁcantly higher LT neutralizing as
ell as anti-LT IgA and IgG antibody responses in serum than the
rst-generation ETEC vaccine containing a comparable dose of CTB.
As in previous studies of oral, inactivated as well as live ETEC
accines in Swedish and American volunteers [5,24], IgA antibody
esponses against all of the different CFs in serum were infrequent
nd low. Serum IgA antibody responses induced by MEV  against
78 LPS were, however, frequent. Fecal and ALS IgA responses
gainst O78 LPS were also observed in a majority of vaccinees.
lthough O78 LPS is only expressed by about 10% of clinical ETEC
solates [25], these responses may  add to the protective coverage of
he vaccine since we have previously shown that anti-O antibodies
ay  provide protection against ETEC expressing the homologous
erogroup [5].
A  combination of LT and CF antigens seems to be required for
road protective coverage. It has been estimated that a vaccine con-
aining LT antigen and the most prevalent CF antigens, as those in
EV  and in an oral, live ETEC candidate vaccine, ACE527, recently
valuated in humans [26], may  have the potential to protect against
t least 80% of all ETEC strains causing disease in humans [1,5]. In
ontrast, a vaccine based on LT antigen alone will not offer protec-
ion against ST-only ETEC strains and is likely to provide shorter
uration of protective immunity [27].
Based on the excellent safety proﬁle and capacity of MEV  to
nduce highly signiﬁcant mucosal immune responses against the
ost prevalent ETEC virulence factors, studies are planned to eval-
ate the safety and immunogenicity of the vaccine alone and in
ombination with different dosages of dmLT in descending-age
roups in Phase I/II trials in Bangladesh and for protective efﬁcacy
n visitors to ETEC-endemic areas.
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